Genpact stock carries a USD 39.33 consensus target

Published on 10/07/2026 at 04:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 revenue reached USD 1.34 billion, up 7.1 percent year over year. The October 6 quote was USD 33.45, with earnings due November 11, 2026.

Genpact, BMG3922B1072, Illustration mit AI erstellt.

Genpact stock (ISIN BMG3922B1072) was last at USD 33.45 on the NYSE on October 6, 2026, with a daily change of -0.21 percent. A nine-analyst consensus assigns the shares a Hold rating and an average target of USD 39.33, according to MarketBeat on October 3, 2026.

Consensus leaves room above price

The average target lies 17.6 percent above the October 6 price. The same MarketBeat report lists two Buy ratings and seven Hold ratings, placing the target above the market quotation while keeping the overall label at Hold.

Recent individual views show a wide spread. Susquehanna raised its target from USD 33.00 to USD 37.00 on August 7, 2026, while Needham cut its target from USD 50.00 to USD 45.00 on the same date, according to MarketBeat.

Q2 revenue grew 7.1 percent

Genpact reported Q2 2026 revenue of USD 1.34 billion, up 7.1 percent from the year-earlier quarter, while adjusted earnings per share reached USD 1.00 against a USD 0.96 estimate, according to Investing.com.

Advanced Technology Solutions revenue increased 24.1 percent to USD 363 million in Q2 2026, representing 27 percent of total revenue, the same Investing.com summary reports. That mix matters because Genpact is using AI-enabled services to shift growth toward higher-value technology work.

Regulatory risk stays visible

A separate legal issue remains part of the company picture. In an order dated September 16, 2026, the Karnataka High Court upheld the seizure of Genpact India's Gurugram office but allowed ordinary business operations to continue, while directing a fresh decision on a proposed USD 100 million GIFT City investment, as Business Standard reported.

Genpact stock stays below yearly high

Genpact stock was last at USD 33.45 on October 6, 2026, against a 52-week range of USD 26.85 to USD 48.64. Its market capitalization was USD 5.7 billion, giving the consensus target a clear valuation checkpoint without turning the analyst estimate into a forecast of its own.